Autopsy report · NCT05610826

Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“0 enrollment”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 1, Phase 2
Sponsor: University of Chicago
Sponsor type: University, hospital or other
Conditions: Pancreatic Neuroendocrine Tumor; Pancreas Cancer
Interventions: cytoreductive surgery; Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy (PRRT); Peptide receptor radionuclide therapy (PRRT)
Participants: 0
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.